Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q06609: Variant p.Thr134Asn

DNA repair protein RAD51 homolog 1
Gene: RAD51
Feedback?
Variant information Variant position: help 134 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Threonine (T) to Asparagine (N) at position 134 (T134N, p.Thr134Asn). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and polar. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In MRMV2; likely pathogenic. Any additional useful information about the variant.


Sequence information Variant position: help 134 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 339 The length of the canonical sequence.
Location on the sequence: help QGGIETGSITEMFGEFRTGK T QICHTLAVTCQLPIDRGGGE The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         QGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGE

                              QGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGE

Mouse                         QGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGE

Bovine                        QGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGE

Rabbit                        QGGIETGSITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGE

Chicken                       QGGIETGSITELFGEFRTGKTQLCHTLAVTCQLPIDRGGGE

Drosophila                    GGGIETGSITEIFGEFRCGKTQLCHTLAVTCQLPISQKGGE

Baker's yeast                 GGGVETGSITELFGEFRTGKSQLCHTLAVTCQIPLDIGGGE

Fission yeast                 QGGVETGSITELFGEFRTGKSQICHTLAVTCQLPIDMGGGE
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 339 DNA repair protein RAD51 homolog 1
Binding site 127 – 134
Alternative sequence 77 – 173 Missing. In isoform 2.
Helix 133 – 143



Literature citations
Abnormal subcortical activity in congenital mirror movement disorder with RAD51 mutation.
Demirayak P.; Onat O.E.; Gevrekci A.O.; Guelsuener S.; Uysal H.; Bilgen R.S.; Doerschner K.; Oezcelik T.S.; Boyaci H.;
Diagn. Interv. Radiol. 24:392-401(2018)
Cited for: VARIANT MRMV2 ASN-134; INVOLVEMENT IN MRMV2; Defining the genetic landscape of congenital mirror movements in 80 affected individuals.
Collins Hutchinson M.L.; St-Onge J.; Schlienger S.; Boudrahem-Addour N.; Mougharbel L.; Michaud J.F.; Lloyd C.; Bruneau E.; Roux C.; Sahly A.N.; Osterman B.; Myers K.A.; Rouleau G.A.; Jimenez Cruz D.A.; Riviere J.B.; Accogli A.; Charron F.; Srour M.;
Mov. Disord. 39:400-410(2024)
Cited for: VARIANTS MRMV2 ASN-134; GLY-184 AND PRO-192; INVOLVEMENT IN MRMV2;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.